You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

CLINICAL TRIALS PROFILE FOR OZANIMOD HYDROCHLORIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for ozanimod hydrochloride

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01628393 ↗	Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients	Completed	Celgene	Phase 2/Phase 3	2012-09-18	This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734). The primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo by showing a reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions from Week 12 to Week 24 in patients with relapsing multiple sclerosis (RMS).
NCT01647516 ↗	Efficacy and Safety Study of Ozanimod in Ulcerative Colitis	Completed	Celgene	Phase 2	2012-12-26	The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).
NCT02047734 ↗	Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis	Completed	Celgene	Phase 3	2013-12-03	This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).
NCT02294058 ↗	Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)	Completed	Celgene	Phase 3	2014-12-03	The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
NCT02531113 ↗	Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease	Completed	Celgene	Phase 2	2015-10-09	The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for ozanimod hydrochloride

Condition Name

Chart
Table

Condition Name for ozanimod hydrochloride
Intervention	Trials
Healthy Volunteers	6
Crohn Disease	5
Multiple Sclerosis	4
Ulcerative Colitis	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for ozanimod hydrochloride
Intervention	Trials
Colitis	7
Sclerosis	7
Multiple Sclerosis	7
Ulcer	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for ozanimod hydrochloride

Trials by Country

Map
Table

Trials by Country for ozanimod hydrochloride
Location	Trials
United States	271
Canada	37
Australia	28
Poland	20
Spain	17
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for ozanimod hydrochloride
Location	Trials
Texas	15
Ohio	13
California	13
North Carolina	12
Florida	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for ozanimod hydrochloride

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for ozanimod hydrochloride
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	11
Phase 2/Phase 3	3
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for ozanimod hydrochloride
Clinical Trial Phase	Trials
Completed	11
Recruiting	10
Not yet recruiting	6
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ozanimod hydrochloride

Sponsor Name

Chart
Table

Sponsor Name for ozanimod hydrochloride
Sponsor	Trials
Celgene	22
Bristol-Myers Squibb	7
Providence Health & Services	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for ozanimod hydrochloride
Sponsor	Trials
Industry	29
Other	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.